Glaxo Settles Cancer Treatment IP Skirmish With Genentech

Law360, New York (March 27, 2012, 3:02 PM EDT) -- GlaxoSmithKline has settled a suit with Genentech Inc. and nonprofit cancer treatment center City of Hope over two patents that relate to blood cancer treatment, Glaxo partner Genmab A/S said Tuesday.

The dispute concerned U.S. Patents No. 6,331,415 and 7,923,221, the "Cabilly patents," which relate to recombinant antibody production for ofatumumab, which also goes by the GSK brand name Arzerra. GSK is Dutch biotech company Genmab's development and commercial collaborator for ofatumumab, according to Genmab.

A Genentech spokeswoman, Robin Snyder, said Genentech was satisfied with the...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.